Charles Schwab stock (SCHW) slides into CPI week as earnings season heats up

Charles Schwab stock (SCHW) slides into CPI week as earnings season heats up

New York, Jan 11, 2026, 16:59 ET — Market closed.

  • Schwab closed last week at $100.17, slipping roughly 1.2% from its previous finish.
  • Tuesday brings U.S. CPI figures alongside major bank earnings, as investors eye potential changes in rate-cut forecasts. (Reuters)
  • Schwab plans to release its Q4 results and host a Winter Business Update webcast on Jan. 21. (About Schwab)

Charles Schwab shares dipped to $100.17 heading into the weekend, shedding roughly 1.2% from the previous close as investors brace for a packed schedule kicking off before Tuesday’s open.

The immediate focus isn’t a Schwab headline. Instead, it’s the broader macro picture and the tape: major banks kick off fourth-quarter earnings on Tuesday, the same day the U.S. Consumer Price Index (CPI) for December drops—a crucial inflation read for the Fed. According to LSEG IBES, analysts expect S&P 500 earnings to climb 13% in 2025, then surge over 15% in 2026, fueling steady appetite for equity risk. “The banks are going to be telling you something … pretty important,” said Jack Janasiewicz, portfolio manager at Natixis Investment Managers. (Reuters)

Schwab is set to spark some movement soon after. The firm plans to unveil its fourth-quarter 2025 earnings with the December monthly activity report around Jan. 21. It’s also lined up a Winter Business Update webcast for that same day. (About Schwab)

Last week ended on a high note for the broader market, unlike Schwab stock. The S&P 500 hit a record closing high Friday, as a softer-than-anticipated U.S. jobs report failed to shake bets on rate cuts later this year, Reuters noted. (Reuters)

Schwab bucked the broader rally, slipping 1.15% Friday to finish at $100.17. That marked its fourth day in a row dropping and left it trailing other financial firms like Morgan Stanley, per MarketWatch data. (MarketWatch)

Rate expectations hold extra weight at Schwab compared to many brokers. A significant portion of its earnings hinges on net interest revenue — the gap between returns on client cash assets and payouts — meaning changes in yields and deposit rates often hit investor models fast.

That’s why Tuesday’s CPI figures matter to SCHW investors, even if Schwab isn’t behind the data. Cooler inflation could boost expectations for more Fed rate cuts. A hotter reading, on the other hand, might delay them. Either way, Treasury yields will react, directly impacting how investors view Schwab’s interest income and funding expenses.

As Schwab reports on Jan. 21, attention will probably shift away from just EPS figures. Instead, investors will zero in on the details: client cash flows, shifts between bank deposits and money-market funds, and whether funding costs are stabilizing. Expenses will also be under the microscope, along with management’s take on 2026 trading volumes following a solid kickoff for major equity indexes.

There is, however, a riskier route. Should inflation pick up again and rate-cut expectations fade, or if stocks drop sharply from their highs, brokerage shares could suffer a double hit — falling asset-based fees alongside reduced trading activity, while concerns around cash management and deposit rivalry resurface.

Tuesday brings the CPI report, along with the initial batch of major bank earnings, kicking off with JPMorgan. After that, all eyes shift to Schwab’s Jan. 21 earnings and Winter Business Update, which will dominate the stock’s attention.

Stock Market Today

  • Profound Medical: Top TSX Growth Stock Poised for Rapid Expansion, Q3 Revenues Surge 87%
    February 1, 2026, 9:22 PM EST. Profound Medical (TSX:PRN), a Canadian medical device firm specializing in MRI-guided ultrasound therapies, is highlighted as the sole TSX growth stock to hold for the next three years. The company reported an 87% revenue increase in Q3 to $5.3 million, driven by expanded installations of its flagship TULSA-PRO prostate cancer treatment system. Offering incision-free, MRI-guided ablation technology, Profound's procedures have gained Medicare approval with rising insurance reimbursements. Despite a net loss of $8 million, the company improved gross margins to 74.3% and ended Q3 with $25 million cash, supporting near-term liquidity. With 70 systems installed and 93 in advanced sales stages, Profound aims for 75 installations by year-end, making it a notable small-cap growth stock in healthcare on the TSX.
Intuit stock heads into tax-season test as IRS sets Jan. 26 start; insiders file moves
Previous Story

Intuit stock heads into tax-season test as IRS sets Jan. 26 start; insiders file moves

Amgen stock on watch as JPMorgan conference speech looms after two-day slide
Next Story

Amgen stock on watch as JPMorgan conference speech looms after two-day slide

Go toTop